lyophilised powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-26. Numbers and descriptions here follow the published literature rather than marketing material.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Stability depends heavily on physical state. Lyophilized powder held dry, cold and dark retains its content over long periods, whereas dissolved peptide begins to change within days at room temperature. The most cited degradation route is oxidation of the methionine residue, which converts the peptide to a sulfoxide form that elutes differently on chromatography. Hydrolysis of amide bonds and adsorption onto container walls contribute smaller losses. Buffers that exclude oxygen from the headspace slow the oxidation pathway, but no single condition prevents all change indefinitely.
Practical handling follows from those properties. Bulk material is best divided into single-use portions soon after receipt, because each thaw exposes the whole container to moisture and temperature cycling. Vials should be allowed to reach room temperature before opening to prevent condensation on the powder. Low-binding plasticware reduces loss of dilute solutions, and sterile filtration is used when a preparation must remain free of microbial growth. Records of batch number, reconstitution date and storage history are what allow a later analytical result to be interpreted meaningfully.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | ACTH(4-7) analogue |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Free N terminus, unmodified side chains |
| Molecular weight | 813.9 Da | Free base; salt forms differ |
| Appearance | White to off-white powder | Lyophilised solid |
| Solubility | Freely soluble in water | Hydrophilic; polar solvents preferred |
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
Purity assessment relies mainly on reversed-phase high-performance liquid chromatography, which separates the target heptapeptide from truncated sequences, deletion analogues, and oxidised forms. Mass spectrometry, usually coupled to liquid chromatography, confirms identity through the expected molecular ion and reveals modifications such as methionine sulfoxide formation. Amino acid analysis can verify composition, and tandem mass spectrometry supports sequence confirmation. Ultraviolet detection near 254 to 280 nanometres is convenient because the phenylalanine and histidine residues absorb in that region. Nuclear magnetic resonance is rarely used for routine release testing.
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
== Diagnosis == Protein function tests that demonstrate a reduce in chorein levels and also genetic analysis can confirm the diagnosis given to a patient. For a disease like this it is often necessary to sample the blood of the patient on multiple occasions with a specific request given to the haematologist to examine the film for acanthocytes. Another point is that the diagnosis of the disease can be confirmed by the absence of chorein in the western blot of the erythrocyte membranes.
=== Cyclin dependent kinases === Cyclin dependent kinases (CDKs) are a group of several different kinases involved in regulation of the cell cycle. They phosphorylate other proteins on their serine or threonine residues, but CDKs must first bind to a cyclin protein in order to be active. Different combinations of specific CDKs and cyclins mark different parts of the cell cycle. Additionally, the phosphorylation state of CDKs is also critical to their activity, as they are subject to regulation by other kinases (such as CDK-activating kinase) and phosphatases (such as Cdc25). Once the CDKs are active, they phosphorylate other proteins to change their activity, which leads to events necessary for the next stage of the cell cycle. While they are most known for their function in cell cycle control, CDKs also have roles in transcription, metabolism, and other cellular events. Because of their key role in the controlling cell division, mutations in CDKs are often found in cancerous cells. These mutations lead to uncontrolled growth of the cells, where they are rapidly going through the whole cell cycle repeatedly. CDK mutations can be found in lymphomas, breast cancer, pancreatic tumors, and lung cancer. Therefore, inhibitors of CDK have been developed as treatments for some types of cancer.
The only confirmed isotope of oganesson, 294Og, has much too short a half-life to be chemically investigated experimentally. Therefore, no compounds of oganesson have been synthesized yet. Nevertheless, calculations on theoretical compounds have been performed since 1964. It is expected that if the ionization energy of the element is high enough, it will be difficult to oxidize and therefore, the most common oxidation state would be 0 (as for the noble gases); nevertheless, this appears not to be the case. Calculations on the diatomic molecule Og2 showed a bonding interaction roughly equivalent to that calculated for Hg2, and a dissociation energy of 6 kJ/mol, roughly 4 times of that of Rn2. Most strikingly, it was calculated to have a bond length shorter than in Rn2 by 0.16 Å, which would be indicative of a significant bonding interaction. On the other hand, the compound OgH+ exhibits a dissociation energy (in other words proton affinity of oganesson) that is smaller than that of RnH+. The bonding between oganesson and hydrogen in OgH is predicted to be very weak and can be regarded as a pure van der Waals interaction rather than a true chemical bond. On the other hand, with highly electronegative elements, oganesson seems to form more stable compounds than for example copernicium or flerovium. The stable oxidation states +2 and +4 have been predicted to exist in the fluorides OgF2 and OgF4. The +6 state would be less stable due to the strong binding of the 7p1/2 subshell. This is a result of the same spin–orbit interactions that make oganesson unusually reactive.
=== Headache Disorders === Both isoforms of PACAP (PACAP-38 and PACAP-27) have been implicated in migraine pathogenesis. A Danish research group led by Dr. Messoud Ashina found that intravenous infusion of PACAP-38 induced migraine attacks in 58% of people with migraine, whilst the corresponding migraine induction rate was 55% for PACAP-27. Treatments with monoclonal antibodies have been investigated to target PACAP or its receptors for the treatment of primary headache disorders. In a phase 2, proof of concept study published in 2024, a monoclonal antibody treatment targeting PACAP (denoted Lu AG09222) reduced the number of migraine days in patients suffering from treatment-resistant migraines. Attempts to target its receptors have been less successful. Amgen's AMG-301, which targets the PAC1 receptor, failed to show greater efficacy than placebo in phase II trials.
Sources: en.wikipedia.org
=== Issues with theories === No single type of theory is satisfactory on its own; social cognition theories poorly address autism's rigid and repetitive behaviors, while most of the nonsocial theories have difficulty explaining autism's social impairment and communication difficulties. A combined theory based on multiple deficits may prove to be more useful.
=== Casting === Upon the series order announcement, Peters, Ramos, Pope, and Ashton Kutcher were cast in starring roles. Rebecca Hall was cast as part of the main cast by the time the series had begun production. In February 2025, it was reported that Isabella Rossellini had joined the cast in a recurring role. In July 2026, it was reported that the entire cast had been released so the actors can pursue other projects.
== History and uses == Ceramic petrography is used in academic archaeological research and commercial archaeology to address a range of issues. A common goal is tracing the movement of pottery and associated trade through provenance determination. The principle of provenance ascription with ceramic petrography relies on the fact that "the mineral and rock inclusions within a paste are a reflection of the geology of the source area of the ceramics" and that potters did not transport ceramic raw materials over significant distances. An equally important concern is the nature of ancient ceramic production and its meaning in terms of the knowledge, skills, identity and traditions of potters. As synthetic materials, ceramics are "sensitive indicators of human decision making and materials interaction". By examining microstructural evidence for processes such as clay paste preparation, forming and firing, ceramic petrographers can reconstruct the steps involved in the production of ceramic artefacts. Ceramic petrography originated in the American Southwest with the work of Anna O. Shepard but has mainly been developed in the Old World in the later half of the 20th century. Other early studies include the work of David Peacock and his students in the UK Ceramic petrography continues to be applied to the interpretation of British ceramics and is used heavily in the prehistoric Aegean. In the USA the approach is less popular, though important contributions have been made in the area of quantitative petrography.
== Use and effects == In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists MMDA's dose as 100 to 250 mg orally and its duration as "moderate". Its onset is described as 20 to 45 minutes. The effects of MMDA have been reported to include relaxation, time dilation, empathy, passivity, compassion, changes in music perception, closed-eye visuals such as geometric patterns, open-eye visuals, dream-like states described as "brain movies", and an afterglow. It has been said to be gentler than certain other psychedelics. The drug is said to have similar effects to MDA, but to be to some extent more psychedelic in comparison.
Suvorexant, sold under the brand name Belsomra, is an orexin antagonist medication used in the treatment of insomnia. It is indicated specifically for the treatment of insomnia characterized by difficulties with sleep onset and/or maintenance in adults. Suvorexant helps with falling asleep faster, sleeping longer, being awake less in the middle of the night, and having better quality of sleep. Its effectiveness is modest, similar to that other orexin antagonists, but it is lower than that of benzodiazepines and Z-drugs. Suvorexant is taken orally. Side effects of suvorexant include somnolence, daytime sleepiness and sedation, headache, dizziness, abnormal dreams, dry mouth, and impaired next-day driving ability. Rarely, sleep paralysis, sleep-related hallucinations, complex sleep behaviors like sleepwalking, and suicidal ideation may occur. Tolerance, dependence, withdrawal, and rebound effects do not appear to occur significantly with the medication. Suvorexant is a dual orexin receptor antagonist (DORA). It acts as a selective dual antagonist of the orexin OX1 and OX2 receptors. The medication has an intermediate elimination half-life of 12 hours and a time to peak of about 2 to 3 hours. Unlike benzodiazepines and Z-drugs, suvorexant does not interact with GABA receptors, instead having a distinct mechanism of action. Clinical development of suvorexant began in 2006 and it was introduced for medical use in 2014. The medication is a schedule IV controlled substance in the United States and may have a modest potential for misuse.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.
It contains the 4-7 fragment of adrenocorticotropic hormone extended at the C terminus. That truncation removes the region associated with steroidogenic activity. The design intent was to keep neurotrophic properties while avoiding full hormonal effects.
No natural source of the intact heptapeptide is known. It is produced by solid-phase peptide synthesis. Some related ACTH fragments arise as hormone processing products, but the Pro-Gly-Pro extension is a designed addition rather than a natural sequence.
Suppliers normally quote a percentage of total chromatographic peak area, most often from reversed-phase HPLC. That figure says nothing about what the remaining percentage contains, and it depends on the detection wavelength used. A mass spectrometry result is a separate and stronger check on identity.